Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 16, Number 7—July 2010

Letter

Mycobacterium conceptionense Infection after Breast Implant Surgery, France

To the Editor: Mycobacterium fortuitum complex members are rapidly growing mycobacteria found in water and soil (1). These opportunistic pathogens are responsible for posttraumatic skin and soft tissue infections. They also account for 60%–80% of postsurgical wound infections caused by rapidly growing mycobacteria (2), particularly after breast surgery (with or without prosthetic implants) (3). M. conceptionense, an emerging member of the M. fortuitum complex, was initially described in a case of osteomyelitis that occurred after an open fracture of the tibia (4). We report a case of M. conceptionense infection that occurred after breast surgery.

A woman 58 years of age had a left mastectomy with lymph node dissection and chemotherapy for breast carcinoma in March 2004. Three years later, she underwent breast reconstruction that used a cutaneomuscular latissimus dorsi flap with a prosthetic implant. Immediately after surgery, a fever (39°C) developed, but 3 blood cultures remained sterile. No treatment was administered, and she became afebrile within 3 days.

At day 15 after surgery, a serous discharge appeared in the tip of the skin flap. By day 21, the patient was again febrile, and the wound discharge was swabbed for analysis. On day 27, she underwent surgical revision with ablation of the breast implant, drainage, and sample collection. The leukocyte count was normal. However, the C-reactive protein level was 99 mg/L, and the erythrocyte sedimentation rate was 111 mm (first hour). Treatment with intravenous amoxicillin/clavulanic acid was started. Although the biologic parameters normalized, the serous discharge continued. Microscopic examination of specimens from days 21 and 27 yielded no bacteria in Gram- and Ziehl-Nielsen–stained pus specimens, and standard bacteriologic cultures remained sterile. M. conceptionense, identified by partial rpoB gene sequencing (100% identity with GenBank accession no. AY859695.1) (4), grew in both specimens after 8 days of incubation at 37°C under a 5% CO2 atmosphere in Coletsos medium (bioMérieux, La Balme-les-Grottes, France). By the Etest method (4), both isolates were susceptible to several antimicrobial drugs, including clarithromycin, amikacin, ciprofloxacin, and doxycycline. The patient was treated with ciprofloxacin, azythromycin, and amikacin for 3 weeks, followed by ciprofloxacin and azythromycin for 4 weeks.

At patient’s relapse 3 months later, M. conceptionense exhibiting identical antimicrobial drug susceptibility pattern was again isolated from the wound fluid. The patient was then treated with ciprofloxacin, azythromycin, and doxycycline for 6 months; subsequently, doxycycline alone was given for a total of 18 months. Results from the 2-month follow-up examination were unremarkable.

M. conceptionense was unambiguously identified by partial rpoB gene sequencing, a first-line tool for accurate identification of nontuberculous mycobacteria (5). A pathogenic role for M. conceptionense was supported by 1) its repetitive isolation from the wound; 2) the absence of any other pathogen; and 3) wound healing during appropriate, long-term antimicrobial drug treatment. However, the source of infection remained unknown. The patient had a tattoo on the skin flap used for the breast reconstruction, and ink has been shown to be a source for rapidly growing mycobacteria other than M. conceptionense (6). However, the tattoo was 5 years old and clinically safe.

Recent reports have identified 12 M. conceptionense isolates from water collected in a cooling tower (7) and 9 isolates from various freshwater fish species (8). The type strain of M. conceptionense had been isolated after prolonged exposure of the patient to fresh water (4). These observations suggest that water is a potential source for M. conceptionense. In this patient, use of contaminated aqueous solutions or inadequately rinsed surgical equipment (9) was unlikely the source of infection because further investigations indicated proper use of sterilized, nonreusable surgical equipment. At home, the patient used well water, but results of tests used to detect M. conceptionense by culture and the presence of the rpoB gene in well water remained negative.

Because M. conceptionense is an emerging pathogen with only 2 reported cases of infection (4,10), the optimal treatment is unknown (Table). Current recommendations for breast implant infection from M. fortuitum include 6 months of appropriate antimicrobial drug treatment in addition to implant removal because surgery alone yields relapse within 4–6 weeks (2,3). Increased worldwide use of breast implants is likely to increase the number of M. conceptionense infections and will raise questions about the optimal management of these infections.

Sandrine Thibeaut, Pierre-Yves Levy, Marie-Laure Pelletier, and Michel DrancourtComments to Author 
Author affiliations: Université de la Méditerranée, Marseille, France (S. Thibeaut, P.-Y. Levy, M. Drancourt); Clinique la Casamance, Aubagne, France (P.-Y. Levy, M.-L. Pelletier)

Acknowledgment

This work was supported by Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes UMR CNRS 6236 IRD 198.

References

  1. Primm TP, Lucero CA. Health impacts of environmental mycobacteria. Clin Microbiol Rev. 2004;17:98106.Falkinham JO III DOIPubMed
  2. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic non-pigmented or late-pigmented rapidly growing Mycobacteria. Clin Microbiol Rev. 2002;15:71646. DOIPubMed
  3. Vinh DC, Rendina A, Turner R, Embil JM. Breast implant infection with Mycobacterium fortuitum group: report of case and review. J Infect. 2006;52:e637. DOIPubMed
  4. Adékambi T, Stein A, Carjaval J, Raoult D, Drancourt M. Description of Mycobacterium conceptionense sp. nov., a Mycobacterium fortuitum group organism isolated from a posttraumatic osteitis inflammation. J Clin Microbiol. 2006;44:126873. DOIPubMed
  5. Adékambi T, Drancourt M, Raoult D. The rpoB gene as a tool for clinical microbiologists. Trends Microbiol. 2009;17:3745. DOIPubMed
  6. Preda VA, Maley M, Sullivan JR. Mycobacterium chelonae infection in a tattoo site. Med J Aust. 2009;190:2789.PubMed
  7. Pagnier I, Merchat M, Raoult D, La Scola B. Emerg Infect Dis. 2009;15:1212.Emerging Mycobacteria spp. in cooling towers. DOIPubMed
  8. Pourahmad F, Thompson KD, Taggart JB, Adams A, Richards RH. Evaluation of the INNO-LiPA mycobacteria v2 assay for identification of aquatic mycobacteria. J Fish Dis. 2008;31:93140. DOIPubMed
  9. Phillips MS, von Reyn CF. Nosocomial infections due to non tuberculous mycobacteria. Clin Infect Dis. 2001;33:136374. DOIPubMed
  10. Liao CH, Lai CC, Huang YT, Chou CH, Hsu HL, Hseuh PR. Subcutaneous abscess caused by Mycobacterium conceptionense in an immunocompetent patient. J Infect. 2009;58:3089. DOIPubMed

Table

DOI: 10.3201/eid1607.090771

Related Links

Top of Page

Table of Contents – Volume 16, Number 7—July 2010

Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Michel Drancourt, Unité des Rickettsies, Faculté de Médecine, Université de la Méditerranée, 27 Blvd Jean Moulin, 13385 Marseille CEDEX 5, France





characters(s) remaining.

Comment submitted successfully, thank you for your feedback.

Comments to the EID Editors

Please contact the EID Editors via our Contact Form.

 

Past Issues

Select a Past Issue:

World Malaria Day - April 25, 2014 - Invest in the future, defeat malaria

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO